Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction: REVIEW

British Journal of Pharmacology

Volumn 156, Issue 5, 2009, Pages 713-727

  Szabo, Csaba ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cell death; Diabetic complications; DNA; Endothelial dysfunction; Mitochondria; Nitric oxide; Oxidative stress; PARP; Peroxynitrite; Superoxide

Indexed keywords

3 AMINOBENZAMIDE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENFOTHIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INO 1001; INSULIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXYNITRITE; PROTEIN KINASE C; PYRIDINE NUCLEOTIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIRTUIN; SUPEROXIDE; THIAMINE DERIVATIVE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; PEROXYNITROUS ACID; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ANTIOXIDANT ACTIVITY; AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CELL LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DNA STRAND BREAKAGE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ESSENTIAL HYPERTENSION; GENE EXPRESSION REGULATION; HUMAN; MITOCHONDRION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; DRUG COMBINATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ALDEHYDE REDUCTASE; ANGIOTENSIN II; ANIMALS; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; PEROXYNITROUS ACID; POLY ADENOSINE DIPHOSPHATE RIBOSE; PROTEIN KINASE C; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 64149103180     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00086.x     Document Type: Review

References (191)

1. Adaikalakoteswari A, Rema M, Mohan V, Balasubramanyam M (2007). Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy. Int J Biochem Cell Biol 39 : 1673 1684.
2. Ali TK, Matragoon S, Pillai BA, Liou GI, El-Remessy AB (2008). Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes 57 : 889 898.
3. Altan VM (2003). The pharmacology of diabetic complications. Curr Med Chem 10 : 1317 1327.
4. Anderson D, Yu TW, Wright J, Ioannides C (1998). An examination of DNA strand breakage in the comet assay and antioxidant capacity in diabetic patients. Mutat Res 398 : 151 161.
5. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M et al. (2006). Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA 103 : 18308 18313.
6. Aronson D (2008). Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 45 : 1 16.
7. Arrick DM, Sharpe GM, Sun H, Mayhan WG (2007). Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase. Microvasc Res 73 : 1 6.
8. Astley S, Langrish-Smith A, Southon S, Sampson M (1999). Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes. Diabetes Care 22 : 1626 1631.
9. Avogaro A, Fadini GP, Gallo A, Pagnin E, de Kreutzenberg S (2006). Endothelial dysfunction in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 16 (Suppl. 1 S39 S45.
10. Bagi Z, Koller A (2003). Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. J Vasc Res 40 : 47 57.
11. Beckman JA (2002). Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90 : 107 111.
12. Bell DS (2003). Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26 : 2433 2441.
13. Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS, Al-Mulla F (2005). Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol 511 : 53 64. (Pubitemid 40380644)
14. Boyle PJ (2007). Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 120 (9 Suppl. 2 S12 S17.
15. Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414 : 813 820.
16. Brownlee M (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 : 1615 1625.
17. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ (2003). ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 46 : 401 408.
18. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY (1999). Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48 : 1856 1862.
19. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M (1988). Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 82 : 735 738.
20. Cai H, Harrison DG (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 : 840 844.
21. Cai H, Griendling KK, Harrison DG (2003). The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24 : 471 478.
22. Calles-Escandon J, Cipolla M (2001). Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22 : 36 52.
23. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L et al. (2001). Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44 : 834 838.
24. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B (2002a). Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25 : 1439 1443.
25. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B et al. (2002b). Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106 : 1211 1218.
26. Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D (2007). Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 30 : 649 654.
27. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R et al. (2008). Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57 : 1349 1354.
28. Chen H, Jia W, Xu X, Fan Y, Zhu D, Wu H et al. (2008). Upregulation of PEDF expression by PARP inhibition contributes to the decrease in hyperglycemia-induced apoptosis in HUVECs. Biochem Biophys Res Commun 369 : 718 724.
29. Chiu J, Farhangkhoee H, Xu BY, Chen S, George B, Chakrabarti S (2008a). PARP mediates structural alterations in diabetic cardiomyopathy. J Mol Cell Cardiol 45 : 385 393.
30. Chiu J, Xu BY, Chen S, Feng B, Chakrabarti S (2008b). Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications. Can J Physiol Pharmacol 86 : 365 372.
31. Chong ZZ, Lin SH, Li F, Maiese K (2005). The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated 'anti-apoptotic' pathways. Curr Neurovasc Res 2 : 271 285.
32. Cohen G, Riahi Y, Alpert E, Gruzman A, Sasson S (2007). The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes. Arch Physiol Biochem 113 : 259 267.
33. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Salvemini D et al. (2001). Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 134 : 21 29.
34. Coppey LJ, Gellett JS, Davidson EP, Yorek MA (2003). Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37 : 33 40.
35. Cosentino F, Luscher TF (1998). Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32 : S54 61.
36. Crocker IP, Kenny LC, Thornton WA, Szabo C, Baker PN (2005). Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br J Pharmacol 144 : 772 780.
37. Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL, Szabó C (1998). Effect of L-buthionine-(S,R)-sulphoximine, an inhibitor of gamma- glutamylcysteine synthetase on peroxynitrite- and endotoxic shock-induced vascular failure. Br J Pharmacol 123 : 525 537.
38. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS et al. (2004). Rosiglitazone, a ligand of the peroxisome proliferator activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483 : 79 93. (Pubitemid 38056607)
39. Da Ros R, Assaloni R, Ceriello A (2004). The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 21 : 1249 1252.
40. Dandona P, Chaudhuri A, Aljada A (2004). Endothelial dysfunction and hypertension in diabetes mellitus. Med Clin North Am 88 : 911 931. (Pubitemid 39090345)
41. Dawson VL, Dawson TM (2004). Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 36 : 287 294.
42. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM (2000). Endothelial dysfunction in diabetes. Br J Pharmacol 130 : 963 974.
43. DeRubertis F, Craven P, Melhem M, Salah E (2004). Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interactions. Diabetes 53 : 762 768.
44. Diederich D, Skopec J, Diederich A, Dai FX (1994). Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 266 : H1153 H1161.
45. Dincer Y, Akcay T, Ilkova H, Alademir Z, Ozbay G (2003). DNA damage and antioxidant defense in peripheral leukocytes of patients with Type I diabetes mellitus. Mutat Res 527 : 49 55.
46. Drel VR, Pacher P, Vareniuk I, Pavlov I, Ilnytska O, Lyzogubov VV et al. (2007a). A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur J Pharmacol 569 : 48 58.
47. Drel VR, Pacher P, Vareniuk I, Pavlov IA, Ilnytska O, Lyzogubov VV et al. (2007b). Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. Int J Mol Med 20 : 783 792.
48. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB et al. (2008). Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med 21 : 667 676.
49. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C et al. (2003). Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112 : 1049 1057.
50. Du X, Edelstein D, Brownlee M (2008). Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 51 : 1930 1932.
51. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001). Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108 : 1341 1348.
52. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB (2003). Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162 : 1995 2004.
53. Engerman RL, Kern TS (1987). Progression of incipient diabetic retinopathy during good glycaemic control. Diabetes 36 : 808 812.
54. Evans J (2008). Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye 22 : 751 760.
55. Förstermann U (2006). Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 387 : 1521 1533.
56. Foster TS (2007). Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ 33 : 111 117.
57. Frye RA (1999). Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260 : 273 279.
58. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K (2002). Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 87 : 264 269. (Pubitemid 34177685)
59. Garcia Soriano F, Virág L, Jagtap P, Szabó É, Mabley JG, Liaudet L et al. (2001). Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7 : 108 113.
60. Giannini C, Lombardo F, Currò F, Pomilio M, Bucciarelli T, Chiarelli F et al. (2007). Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus. Diabetes Metab Res Rev 23 : 539 546.
61. Gibson TM, Cotter MA, Cameron NE (2006). Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats. Nitric Oxide 15 : 344 350.
62. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006). Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 : 597 605.
63. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R et al. (2000). Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 86 : 85 90.
64. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R et al. (2002). Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105 : 1656 1662.
65. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q et al. (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 : 294 299.
66. Hassa PO, Haenni SS, Elser M, Hottiger MO (2006). Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 70 : 789 829.
67. Hattori Y, Kawasaki H, Abe K, Kanno M (1991). Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 261 : H1086 H1094.
68. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M et al. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88 : E14 E22.
69. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Baylis C (2003). Peroxynitrite versus nitric oxide in early diabetes. Am J Hypertens 16 : 761 766.
70. Horváth EM, Benko R, Gero D, Kiss L, Szabó C (2008). Treatment with insulin inhibits poly(ADP-ribose)polymerase activation in a rat model of endotoxemia. Life Sci 82 : 205 209.
71. Horvath EM, Benko R, Kiss L, Muranyi M, Pek T, Fekete K (2009). Rapid "glycaemic swings" induce nitrosative stress, activate poly (ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia in press.
72. Ihnat MA, Thorpe JE, Kamat CD, Szabó C, Green DE, Warnke LA et al. (2007). Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia 50 : 1523 1531.
73. Ilnytska O, Lyzogubov VV, Stevens MJ, Drel VR, Mashtalir N, Pacher P et al. (2006). Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 55 : 1686 1694.
74. Inoguchi T, Tsubouchi H, Etoh T, Kakimoto M, Sonta T, Utsumi H et al. (2003). A possible target of antioxidative therapy for diabetic vascular complications-vascular NAD(P)H oxidase. Curr Med Chem 10 : 1759 1764.
75. Jagtap P, Szabó C (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4 : 421 440. (Pubitemid 40704125)
76. Kashiwagi A, Nishio Y, Asahina T, Ikebuchi M, Harada N, Tanaka Y et al. (1997). Pyruvate improves deleterious effects of high glucose on activation of pentose phosphate pathway and glutathione redox cycle in endothelial cells. Diabetes 46 : 2088 2095.
77. Kossenjans W, Eis A, Sahay R, Brockman D, Myatt L (2000). Role of peroxynitrite in altered fetal-placental vascular reactivity in diabetes or preeclampsia. Am J Physiol Heart Circ Physiol 278 : H1311 H1319.
78. Kowluru RA, Odenbach S (2004). Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53 : 3233 3238.
79. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL (2008). Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 319 : 819 821.
80. Kruszewski M, Szumiel I (2005). Sirtuins (histone deacetylases III) in the cellular response to DNA damage - facts and hypotheses. DNA Repair (Amst) 4 : 1306 1313.
81. Kuchmerovska T, Shymanskyy I, Donchenko G, Kuchmerovskyy M, Pakirbaieva L, Klimenko A (2004). Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy. J Diabetes Complications 18 : 198 204.
82. Kuroki M, Voest E, Amano S, Beerepoot L, Takashima S, Tolentino M et al. (1996). Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98 : 1667 1675.
83. Laakso M (1999). Hyperglycaemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim Care 26 : 829 839. (Pubitemid 29523602)
84. Lee A, Chung S (1999). Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13 : 23 30.
85. Lee TS, Saltsman KA, Ohashi H, King GL (1989). Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 86 : 5141 5145.
86. Leung D, Cachianes G, Kunang W, Goeddel D, Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 : 1306 1309.
87. Li F, Szabó C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T et al. (2004). Evaluation of orally actrive poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 47 : 710 717.
88. Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vom Hagen F et al. (2006). Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia 49 : 1089 1096.
89. Lorenzo HK, Susin SA (2007). Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updat 10 : 235 255.
90. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I et al. (1998). Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101 : 1219 1224.
91. Lyall F, Gibson JL, Greer IA, Brockman DE, Eis AL, Myatt L (1998). Increased nitrotyrosine in the diabetic placenta: evidence for oxidative stress. Diabetes Care 21 : 1753 1758.
92. Mabley JG, Feng Y, Hagen F, Lin J, Brownlee M, Szabó C et al. (2004). Poly(ADP-ribose) polymerase and diabetic retinopathy. FASEB J 18 : A1189.
93. Mabley JG, Horváth EM, Murthy KG, Zsengellér Z, Vaslin A, Benko R et al. (2005). Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J Pharmacol Exp Ther 315 : 812 820.
94. Mabley JG, Wallace R, Pacher P, Murphy K, Szabó C (2007). Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int J Mol Med 19 : 947 952.
95. Mayhan WG (1989). Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am J Physiol 256 : H621 H625.
96. Meraji S, Jayakody L, Senaratne MP, Thomson AB, Kappagoda T (1987). Endothelium-dependent relaxation in aorta of BB rat. Diabetes 36 : 978 981.
97. Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, Bauer JA (2003). Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. Biochem Pharmacol 65 : 1189 1197.
98. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y et al. (2008). Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 28 : 341 347.
99. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjáti K, Pacher P et al. (2003). Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 17 : 1514 1516.
100. Molnár A, Tóth A, Bagi Z, Papp Z, Edes I, Vaszily M et al. (2006). Activation of the poly(ADP-ribose) polymerase pathway in human heart failure. Mol Med 12 : 143 152.
101. Molnar J, Yu S, Mzhavia N, Pau C, Chereshnev I, Dansky HM (2005). Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res 96 : 1178 1184.
102. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. (2006). Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 : 1681 1687.
103. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M et al. (1998). Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101 : 1905 1915.
104. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E (2008). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 40 : 180 196.
105. Nangle M, Cotter M, Cameron N (2004). Effects of the peroxynitrite decomposition catalyst, FeTMPyP, on function of corpus cavernosum from diabetic mice. Eur J Pharmacol 502 : 143 148.
106. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 : 787 790.
107. Oates P, Mylari B (1999). Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 8 : 2095 2119.
108. Obrosova I, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens M et al. (2005). Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-Ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 54 : 234 242.
109. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P et al. (2004a). Poly(ADP-Ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor (VEGF) overexpression. Int J Mol Med 14 : 55 64.
110. Obrosova IG, Li F, Abatan OI, Komjáti K, Pacher P, Szabó C et al. (2004b). Role for poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53 : 711 720.
111. Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT et al. (2007). Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 293 : E1645 E1655.
112. Obrosova IG, Xu W, Lyzogubov VV, Ilnytska O, Mashtalir N, Vareniuk I et al. (2008). PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 44 : 972 981.
113. Oei SL, Ziegler M (2000). ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose). J Biol Chem 275 : 23234 23239.
114. Oyama Y, Kawasaki H, Hattori Y, Kanno M (1986). Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 132 : 75 78.
115. Pacher P, Szabó C (2006). Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 6 : 136 141. (Pubitemid 43362126)
116. Pacher P, Szabó C (2007). Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 25 : 235 260.
117. Pacher P, Szabo C (2008). Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 173 : 2 13.
118. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó É, Szabó C (2002). The role of poly(ADP-ribose) polymerase in the development of myocardial and endothelial dysfunction in diabetes mellitus. Diabetes 51 : 514 521. (Pubitemid 34764811)
119. Pacher P, Beckman JS, Liaudet L (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 : 315 424.
120. Pannirselvam M, Verma S, Anderson TJ, Triggle CR (2002). Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 136 : 255 263.
121. Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K et al. (2004). Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose)polymerase. J Thromb Haemost 2 : 1453 1459.
122. Piconi L, Corgnali M, Da Ros R, Assaloni R, Piliego T, Ceriello A (2008). The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose. J Diabetes Complications 22 : 38 45.
123. Pieper GM, Langenstroer P, Gross GJ (1993). Hydroxyl radicals mediate injury to endothelium-dependent relaxation in diabetic rat. Mol Cell Biochem 122 : 139 145.
124. Pillai JB, Isbatan A, Imai S, Gupta MP (2005). Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 280 : 43121 43130.
125. Porcu M, Chiarugi A (2005). The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci 26 : 94 103.
126. Pricci F, Leto G, Amadio L, Iacobini C, Cordone S, Catalano S et al. (2003). Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. Free Radic Biol Med 35 : 683 694.
127. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A (2003). Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52 : 2795 2804.
128. Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Zuodar G et al. (2005). Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 183 : 259 267.
129. Quagliaro L, Piconi L, Assaloni R, Da Ros R, Szabó C, Ceriello A (2007). Primary role of superoxide anion generation in the cascade of events leading to endothelial dysfunction and damage in high glucose treated HUVEC. Nutr Metab Cardiovasc Dis 17 : 257 267.
130. Radovits T, Lin LN, Zotkina J, Gero D, Szabó C, Karck M et al. (2007). Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur J Pharmacol 564 : 158 166. (Pubitemid 46946861)
131. Ramasamy R, Yan SF, Schmidt AM (2005). The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc Med 15 : 237 243.
132. Reusch JE (2003). Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? J Clin Invest 112 : 986 988.
133. Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A (2001). Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 281 : E924 E930
134. Rosca MG, Mustata TG, Kinter MT, Odzemir AM, Kern TS, Szweda LI et al. (2005). Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289 : F420 F430.
135. Rösen P, Ballhausen T, Bloch W, Addicks K (1995). Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 38 : 1157 1168.
136. Roy S, Sala R, Cagliero E, Lorenzi M (1990). Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 87 : 404 408.
137. Ruderman NB, Williamson JR, Brownlee M (1992). Glucose and diabetic vascular disease. FASEB J 6 : 2905 2914.
138. Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, Haruna Y et al. (2008). Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 23 : 3806 3813.
139. Savitha S, Tamilselvan J, Anusuyadevi M, Panneerselvam C (2005). Oxidative stress on mitochondrial antioxidant defense system in the aging process: role of DL-alpha-lipoic acid and L-carnitine. Clin Chim Acta 355 : 173 180.
140. Scivittaro V, Ganz M, Weiss M (2000). AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278 : F676 F683.
141. Scott B, Aruoma O, Evans P, O'Neill C, Van der Vliet A, Cross C et al. (1994). Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Rad Res 20 : 119 123.
142. Sharma SS, Kumar A, Kaundal RK (2008). Protective effects of 4-amino1,8-napthalimide, a poly(ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci 82 : 570 576.
143. Sheetz M, King GL (2002). Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288 : 2579 2588.
144. Shrikhande G, Khaodhiar L, Scali S, Lima C, Hubbard M, Dudley K et al. (2006). Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J Vasc Surg 43 : 760 770.
145. Siragy HM (2008). Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep 10 : 261 267.
146. Song Z, Fu D, Chan Y, Leung S, Chung S, Chung S (2003). Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 23 : 638 647.
147. Soriano FG, Mabley JG, Pacher P, Liaudet L, Szabó C (2001). Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 89 : 684 691. (Pubitemid 34627068)
148. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116 : 2552 2561.
149. Stevens MJ, Li F, Drel VR, Abatan OI, Kim H, Burnett D et al. (2007). Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 320 : 58 64.
150. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C et al. (2006). Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29 : 2064 2071.
151. Stratton I, Adler AI, Neil H, Matthews D, Manley S, Cull C et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 : 405 412. (Pubitemid 30609442)
152. Sugawara R, Hikichi T, Kitaya N, Mori F, Nagaoka T, Yoshida A et al. (2004). Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr Eye Res 29 : 11 16.
153. Szabó C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL (1997). Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly(ADP-ribose) synthetase by peroxynitrite. J Clin Invest 100 : 723 735.
154. Szabo C, Virag L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP et al. (1998). Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 95 : 3867 3872.
155. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC et al. (2002a). Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 106 : 2680 2686.
156. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L et al. (2002b). Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8 : 571 580.
157. Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R et al. (2004). Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10 : 28 35.
158. Szabo C, Pacher P, Swanson RA (2006a). Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol Sci 27 : 626 630.
159. Szabó C, Biser A, Benko R, Böttinger E, Suszták K (2006b). Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice. Diabetes 55 : 3004 3012.
160. Szabó C, Ischiropoulos H, Radi R (2007). Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6 : 662 680.
161. Tagliabue M, Pinach S, Di Bisceglie C, Brocato L, Cassader M, Bertagna A et al. (2005). Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus. Int J Androl 28 : 156 162.
162. Taylor PD, Poston L (1994). The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 113 : 801 808.
163. Tesfamariam B (1994). Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 16 : 383 391.
164. Tesfamariam B, Cohen RA (1992). Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 263 : H321 H326.
165. Thies RL, Autor AP (1991). Reactive oxygen injury to cultured pulmonary artery endothelial cells: mediation by poly(ADP-ribose) polymerase activation causing NAD depletion and altered energy balance. Arch Biochem Biophys 286 : 353 363.
166. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM (2000). Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57 : 1968 1972.
167. Tikoo K, Tripathi DN, Kabra DG, Sharma V, Gaikwad AB (2007). Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Lett 581 : 1071 1078.
168. Tilton RG, Dixon RA, Brock TA (1997). Growth factor antagonists for the treatment of diabetic vascular complications. Expert Opin Investig Drugs 6 : 1671 1684.
169. Vareniuk I, Pavlov IA, Drel VR, Lyzogubov VV, Ilnytska O, Bell SR et al. (2007). Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp Neurol 205 : 425 436.
170. Vaughan TB, Ovalle F, Moreland E (2007). Vascular disease in paediatric type 2 diabetes: the state of the art. Diab Vasc Dis Res 4 : 297 304.
171. Venugopal SK, Devaraj S, Yang T, Jialal I (2002). Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycaemic conditions via inhibition of protein kinase C-alpha. Diabetes 51 : 3049 3054.
172. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS et al. (1998). Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47 : 457 463.
173. Virag L, Szabo C (2002). The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54 : 375 429.
174. Virág L, Scott GS, Cuzzocrea S, Marmer D, Salzman AL, Szabó C (1998a). Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly (ADP-ribose) synthetase (PARS) activation. Immunology 94 : 345 355.
175. Virag L, Salzman A, Szabo C (1998b). Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol 161 : 3753 3759.
176. Voinea M, Georgescu A, Manea A, Dragomir E, Manduteanu I, Popov D et al. (2004). Superoxide dismutase entrapped-liposomes restore the impaired endothelium-dependent relaxation of resistance arteries in experimental diabetes. Eur J Pharmacol 484 : 111 118.
177. Wacker DA, Ruhl DD, Balagamwala EH, Hope KM, Zhang T, Kraus WL (2007). The DNA binding and catalytic domains of poly(ADP-ribose) polymerase 1 cooperate in the regulation of chromatin structure and transcription. Mol Cell Biol 27 : 7475 7485.
178. Wadham C, Parker A, Wang L, Xia P (2007). High glucose attenuates protein S-nitrosylation in endothelial cells: role of oxidative stress. Diabetes 56 : 2715 2721.
179. Wahlberg G, Carlson LA, Wasserman J, Ljungqvist A (1985). Protective effect of nicotinamide against nephropathy in diabetic rats. Diabetes Res 2 : 307 312.
180. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA (2000). Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 14 : 271 278.
181. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. (1993). Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42 : 801 813.
182. Xiao CY, Chen M, Zsengellér Z, Szabó C (2004). Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther 310 : 498 504.
183. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou Y et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptor/binding proteins. J Biol Chem 269 : 9889 9897.
184. Ying W, Chen Y, Alano CC, Swanson RA (2002). Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J Cereb Blood Flow Metab 22 : 774 779.
185. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM et al. (2006). Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 103 : 18314 18319.
186. Zeng J, Yang GY, Ying W, Kelly M, Hirai K, James TL et al. (2007). Pyruvate improves recovery after PARP-1-associated energy failure induced by oxidative stress in neonatal rat cerebrocortical slices. J Cereb Blood Flow Metab 27 : 304 315. (Pubitemid 46148457)
187. Zhang C, Yang J, Jennings LK (2004). Leukocyte-derived myeloperoxidase amplifies high-glucose - induced endothelial dysfunction through interaction with high-glucose - stimulated, vascular non - leukocyte-derived reactive oxygen species. Diabetes 53 : 2950 2959.
188. Zheng L, Szabó C, Kern TS (2004). Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53 : 2960 2967.
189. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA et al. (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29 : 2365 2370.
190. Zou MH, Shi C, Cohen RA (2002). High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51 : 198 203.
191. Zsengeller Z, Mabley JG, Szabó C (2004). High glucose induced endothelial dysfunction: mitochondrial uncoupling inhibits DNA single strand breakage and PARP activation. FASEB J 18 : A1185.